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Rabbit antibodies were prepared against both purified catalytic (component-B) and purified non-catalytic (component-A) 
subunits of crotoxin, the major phospholipase & neurotoxin from the South American rattlesnake. They cross-react with 
crotoxin-like toxins from the venom of several Crotalus species as well as with single-chain phospholipase A2 neurotoxins 
from Crotalid and Viperid venoms (agkistrodontoxin and ammodytoxin A) but not from Elapid venoms (notexin). Im- 
munological cross-reactions of anti-component-A and anti-component-B sera with crotoxin and with its isolated compo- 
nents A and B showed that component-A exposes determinants of low immunogenicity which are present on component- 
B, whereas the major antigenic determinants of component-B are not present on component-A. Anti-component-B anti- 
bodies, but not anti-component-A antibodies, neutralize the lethal potency of crotoxin and inhibit its enzymatic activity. 
Furthermore, non-precipitating anti-component-B Fab fragments were as potent as antibodies, indicating that crotoxin 
neutralization results from the binding of the antibodies to the catalytic subunit, rather than the formation of an immuno- 
precipitate. 
Phospholipase 4; Snake venom neurotoxin; Lethal potency neutralization; Enzymatic inhibition; Neutralizing antibody; 
Neutralizing Fab 
1. INTRODUCTION 
Crotoxin, the major toxic component of the 
venom of the South American rattlesnake, 
Crotalus durissus terrificus [l], is a potent 
neurotoxin which possesses aphospholipase AZ ac- 
tivity and exerts its pathophysiological action by 
blocking neuromuscular transmission [2]. It acts 
primarily at the presynaptic level by altering 
neurotransmitter elease [3-61, like other snake 
neurotoxins that possess a phospholipase AZ activi- 
ty: fl-bungarotoxin [7-91, notexin [lo], taipoxin 
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[11,121, caudoxin [ 13) and agkistrodontoxin 
[14,15]. In addition to its presynaptic action, 
crotoxin also acts postsynaptically, by blocking the 
acetylcholine response through stabilization of the 
acetylcholine receptor in an inactive state that 
resembles the desensitized state [2,16,17]. 
Crotoxin consists of two non-identical subunits: 
a basic and weakly toxic phospholipase AZ, 
component-B, and an acidic component-A which 
is devoid of enzymatic activity and is non-toxic 
[18-201. Components A and B are tightly 
associated in the crotoxin complex and can be 
separated in 6 M urea [21,22]. Component-B is a 
single polypeptide chain of 122 amino acids and its 
sequence is homologous to that of other 
phospholipases A2 from pancreas and snake 
venoms [23,24]. Component-A consists of three 
polypeptide chains linked by seven disulfide 
bridges [25]; their amino acid sequences are 
homologous to various parts of a phospholipase 
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AZ, suggesting that component-A is produced by 
limited proteolysis of a phospholipase precursor 
[26]. Further investigations revealed that purified 
crotoxin is in fact a mixture of several isoforms 
having similar pharmacological and enzymatic 
properties, as expected on the basis of their similar 
polypeptide structure, although they slightly but 
significantly differ in specific activity and lethal 
potency [27,28]. 
The two non-identical subunits of crotoxin act in 
a synergistic manner: component-B alone is weakly 
toxic and may block neuromuscular transmission 
like the whole toxin, although larger doses are re- 
quired to cause the same effect; component-A is 
non-toxic by itself, but applied in combination 
with component-B, it enhances its phar- 
macological efficacy [4,5,17-191. Binding ex- 
periments showed that the two subunits of 
crotoxin separate upon interaction with biological 
membranes: component-B binds while component- 
A is released in solution. The isolated 
phospholipase subunit, component-B, adsorbs to 
membranes in a non-saturable manner, whereas in 
the presence of component-A, it binds to a limited 
number of high-affinity binding sites [17,29]. 
Although the target acceptor site of crotoxin on 
synaptic membranes has not yet been formally 
identified, binding experiments carried out with 
vesicles of various lipid compositions suggested 
that negatively charged phospholipids are an im- 
portant component of this target [30]. 
Crotoxin-like toxins are widely distributed in the 
venom of Crotalus species, and have been purified 
from C. s. scutulatus [31-331, C. viridis concolor 
[34] and C. vegrandis [35]. Since antivenoms are 
widely used to neutralize the lethal effect of snake 
venoms, it is of interest o examine the mechanism 
of neutralization by specific antibodies to 
crotoxin-like toxins, which are the major toxic pro- 
teins of Crotalus venoms. In this investigation, we 
raised rabbit antisera against both isolated crotox- 
in components. We prepared antibodies and Fab 
fragments from anti-component-B sera and ex- 
amined their capacity to neutralize the lethal 
potency of crotoxin and to inhibit its 
phospholipase AZ activity. 
2. EXPERIMENTAL 
Crotoxin from C. &r&us terrificus venom (collected in 
168 
Brazil) and its isolated components A and B were purified as 
described by Hendon and Fraenkel-Conrat [19]. Component-A 
and component-B were emulsified with 50% Freund’s adjuvant 
and were administered S.C. at 3-week intervals. Boosts, which 
were performed when the serum titers were decreasing, were 
achieved by injecting i.m. the same components, in the presence 
of incomplete Freund’s adjuvant. Two immunization protocols 
were performed, they differed by the dose of administered an- 
tigen (50 or 750 pg per rabbit). Three rabbits were immunized 
with each protocol. 
Microtitration plates (96 wells) were coated in phosphate- 
buffered saline (PBS) by overnight incubation of antigen 
(1 p&ml) and saturation was carried out with 5% milk powder 
in PBS. Plates were washed with PBS containing 0.1% 
Tween-20. The solutions to be tested (lOO~l/well), diluted in 
PBS containing 5% milk, were incubated 1 h at 37”C, then 
washed. ,&Galactosidase-labeled goat antibodies anti-rabbit im- 
munoglobulin (Biosys, Compitgne) were added at a 1 : 3000 
dilution, incubated 1 h at 37°C and washed. Substrate for /3- 
galactosidase (100 mM sodium phosphate, pH 7.0, containing 
1 mM Mg-Titriplex, 1 mM MnSO.,, 1 mM MgSO+ 10 mM S- 
methylcysteine and 2.65 mM p-nitrophenyl-@-D-galactoside) 
were added and the absorbance recorded at 405 nm with a 
Dynatech microplate reader. Chase experiments were perform- 
ed by preincubating the sera to be tested with a series of concen- 
trations of the antigen used to coat the titration plates, in PBS 
containing 5% milk. 
Inhibition of phospholipase A2 activity was carried out by 
preincubating for 1 h at 37°C a fixed concentration of enzyme 
(20 /g/ml) with variable amounts of serum, antibodies or Fabs 
and by testing the residual enzymatic activity by titrimetry [36], 
using egg lecithin solubilized by sodium cholate, or non- 
micellar dihexanoyl-L-a-lecithin, as substrates [37,38]. The 
neutralization potency of serum, antibodies or Fabs was deter- 
mined by incubation for 1 h at 37°C of a fixed concentration 
of toxin (usually 20 LDso/ml) with dilutions of the solution to 
be tested. Aliquots (0.2 ml per 20 g body weight) were then in- 
jected i.v. in mice, to estimate the residual lethal potency. The 
toxin neutralizing capacity (ED~o), expressed as sg crotoxin 
neutralized per mg antibodies, was the dose of antibodies that 
neutralized 50% of the crotoxin lethal potency. 
3. RESULTS AND DISCUSSION 
We immunized rabbits with isolated component- 
A and isolated component-B from crotoxin. Table 
1 shows that the antiserum directed against 
component-B has a much higher ELISA titer than 
that directed against component-A. This is consis- 
tent with previous reports, showing that 
component-B is much more antigenic than 
component-A [39]. Immunization protocols differ- 
ing by the quantity of injected antigen gave very 
similar results (not shown), indicating that isolated 
component-A is a weak antigen. 
In a first series of experiments, we examined the 
immunological cross-reactions by ELISA. The 
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Table 1 
ELISA titers of anti-component-A and anti-component-B sera 
Anti- Anti- 
component-B component-A 
Component-B 
Component-A 
Crotoxin 
Agkistrodontoxin 
Ammodytoxin A 
Notexin 
,&Bungarotoxin 
C. adamanteus phospholipase 
V. berus phospholipase 
B. atrox phospholipase 
N. nigricoliis phospholipase 
Porcine pancreas phospho- 
lipase 
l/11000 (0.13) 
> l/l 
l/l0000 (0.5) 
l/2500 (0.1) 
l/40 (0.1) 
> l/l 
>l/l 
> l/l 
> l/2 (n.i.) 
>l/l 
> l/2 (n.i.) 
> l/l 
l/500 (0.03) 
l/300 (0.2) 
l/400 (0.2) 
l/150 (0.1) 
l/10 
>l/l 
>l/l 
> l/l 
> l/l 
>I/1 
> l/l 
>l/l 
C. d. terrificus venom 
(Brazil) l/4000 (0.2) l/200 (0.2) 
C. d. terrificus venom 
(Columbia) l/5000 (0.2) l/250 (0.3) 
C. d. cascaveila venom 
(Brazil) l/6000 (0.15) l/100 (0.3) 
C. s. scutulatus venom (USA) 117000 (0.2) l/100 (0.2) 
ELISA titers were defined as the serum dilution that produced 
half of the maximal response. Numbers in parentheses are the 
concentrations of antigens (in pg/ml) responsible for half- 
reduction of the maximal ELISA response in chase 
experiments. The indicated values are the means of three 
independent experiments, standard deviations being + 10%; 
n.i. indicates that the ELISA titer was not detectably decreased 
in chase experiments 
anti-component-A serum reacts with crotoxin and 
with its isolated component-B (table 1). This obser- 
vation, which is in agreement with a previous study 
of Kaiser et al. [39], may result from the similarity 
of the protein structure of the two subunits [26]. 
On the other hand, anti-component-B serum reacts 
with crotoxin but, at variance with the observation 
of Kaiser et al. [39], does not react with isolated 
component-A. This non symmetrical im- 
munological relationship might be due to a con- 
tamination of the component-A preparation by 
component-B. In order to test this hypothesis, we 
first estimated the presence of component-B in the 
preparation of component-A by measuring its 
phospholipase activity and we found that the con- 
tamination was less than 0.01%. We also frac- 
tionated the anti-component-A serum by affinity 
chromatography on a component-A column and 
observed that the protein peak which did not ad- 
sorb to the column reacted neither with 
component-A nor with component-B, whereas the 
immunoglobulins which adsorbed to the column 
and were eluted at pH 2.0 (100 mM glycine-HCI) 
reacted with both components (not shown). 
Therefore, the non-symmetrical immunological 
relationship between crotoxin subunits cannot be 
attributed to a contamination of component-A by 
component-B. It may be explained by the fact that 
component-A exposes determinants of low im- 
munogenicity which are also present on 
component-B, whereas the major immunogenic 
determinants of component-B are not present on 
component-A. This may be related to the fact that 
component-A most probably derives by limited 
proteolysis from a precursor which is closely 
homologous to component-B [26]. 
We further analyzed the immunological cross- 
reaction of anti-component-A and anti- 
component-B sera with toxic and non-toxic 
phospholipases AZ from snake venom and with 
porcine pancreas phospholipase AZ. Both sera 
strongly react with C. durissus terrificus, C.d. 
cascavella and C.S. scutulatus venoms which are 
known to contain crotoxin-like toxins (table 1). 
Both sera also cross-react with agkistrodontoxin 
and more weakly with ammodytoxin A, which are 
phospholipase A2 neurotoxins from the Crotalid or 
Viperid snakes, Agkistrodon halys pallas [ 14,151 
and Vipera a. ammodytes [40], constituted of a 
single polypeptide chain. Neither anti-component- 
A nor anti-component-B serum shows any cross- 
reaction with the other toxic and non-toxic 
phospholipases A2 listed in table 1, including the 
single-chain neurotoxin, notexin, from the venom 
of an Elapid snake, Notechis s. scutatus. Im- 
munological similarities and differences between 
crotoxin, agkistrodontoxin and ammodytoxin A 
have been confirmed by reciprocal cross-reaction 
performed with rabbit sera prepared with 
agkistrodontoxin and ammodytoxin A (not 
shown). These observations are in agreement with 
those of Kaiser et al. [39] who reported that neither 
anti-component-A nor anti-component-B sera 
cross-react with P-bungarotoxin and 
phospholipases A2 from Naja naja atra venom. On 
the other hand, they disagree to some extent with 
the conclusion of Middlebrook and Kaiser [41] 
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who reported that an anti-crotoxin serum, which 
cross-reacts with crotoxin-like toxins and single- 
chain phospholipase neurotoxins from Viperid 
venoms, also cross-reacts weakly with & 
bungarotoxin and notexin from Elapid venoms. 
Similarly, Nicholson et al. [42] recently reported 
that about 50% of mouse sera prepared against 
notexin cross-react with crotoxin. These dif- 
ferences may be due to the different immunization 
protocols and/or the sensitivity of the ELISA used 
to assess immunological cross-reactions. 
We observed that anti-component-B serum also 
neutralized the lethal potency of crotoxin and in- 
hibited its phospholipase activity (table 2). This 
observation, which is in agreement with a previous 
study of Da Silva and Bier [43], prompted us to 
purify specific anti-component-B antibodies. This 
was achieved by a double ammonium sulfate 
precipitation at 30% saturation and by an im- 
munoaffinity chromatography on a column of 
component-B. Table 2 indicates that, as could be 
expected, the capacity of antibodies to neutralize 
the lethal potency of crotoxin and to inhibit its 
phospholipase activity increased in a parallel man- 
ner, about 30-fold during purification. It is also of 
interest that the same amount of anti-component- 
B antibodies was required to neutralize either the 
lethal potency or the phospholipase AZ activity of 
crotoxin (table 2). 
We prepared monovalent fragments (Fab) by 
limited proteolysis of anti-component-B antibodies 
with papain. Fabs were further purified by ion- 
exchange chromatography on CM-cellulose and 
chromatography on a protein A column. When 
tested for their ability to neutralize the lethal 
potency of crotoxin and to inhibit its 
phospholipase activity, the anti-component-B Fabs 
were slightly but significantly more efficient than 
the intact antibodies (table 2). This indicates that 
crotoxin neutralization results from the binding of 
the antibodies to the catalytic subunit, rather than 
the formation of an immunoprecipitate. Fig. 1 fur- 
ther shows that the anti-component-B Fab 
fragments inhibit more efficiently the 
phospholipase activity of crotoxin component-B 
when measured with monodispersed substrate than 
when determined with mixed micelles of 
phospholipids and detergent. This indicates that 
the inhibition of the phospholipase activity does 
not result from a blockade of the binding of 
component-B to micelles or biological membranes 
but is the consequence of a direct or allosteric in- 
hibition of enzymatic catalysis. 
Because of the synergistic action of the two 
crotoxin subunits, neutralization of the lethality of 
crotoxin might result from the dissociation of the 
toxin complex. We incubated crotoxin with 
neutralizing doses of anti-component-B Fabs and 
checked, by polyacrylamide gel electrophoresis 
(under non-denaturing conditions), the formation 
Table 2 
Neutralization of crotoxin lethal potency and inhibition of its phospholipase activity by 
anti-component-B or anti-component-A antibodies and Fabs 
Antibody Protein 
mg Yield 
ELISA Crotoxin 
titer 
bg/ml) PLAz EDso 
Ocg/mg) @g/mg) 
Anti-component-B 
Serum 36800 100 9.5 0.8 0.5 
Ammonium sulfate precipitate 9200 25 5.6 1.8 1.9 
Immunoaffinity column 900 2.4 0.56 14 14 
Fab 200 0.5 14.5 22 20 
Anti-component-A 
Serum 36000 100 300 < 0.005 <0.004 
Ammonium sulfate 10125 25 150 <O.Ol <O.Ol 
Immunoaffinity column 932 2.5 ND <0.02 <0.02 
Protein concentrations were estimated by the method of Folin. Neutralization and 
inhibition capacities determined with micellar substrate are expressed in pg crotoxin 
neutralized or inhibited per mg protein. ND, not done 
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Fob cOnCBnlrtlion lmo~mll 
Fig.1. Inhibition of phospholipase AZ activity by anti- 
component-B Fabs. Crotoxin (squares) or its isolated 
component-B (circles) were incubated at a concentration of 
20 rg/ml with the indicated concentrations of anti-component- 
B Fabs. The residual phospholipase Al activity was measured 
by titrimetry, using mixed micelles of egg lecithin and sodium 
cholate (open symbols) or dihexanoyl-L-a-lecithin in a 
monodispersed form, i.e. at a concentration below their critical 
micellar concentration (closed symbols). 
C 
Fig.2. Anti-component-B Fabs do not dissociate the crotoxin 
complex. Crotoxin (10 pM, 0.25 mg/ml) was incubated for 1 h 
with anti-component-B Fab (20 pM, 1 mg/ml), then submitted 
to non-denaturing PAGE. Gels were stained with Coomassie 
brilliant blue. (A) Anti-component-B Fab; (B) crotoxin and 
anti-component-B Fab; (C) crotoxin; (D) component-A. 
of Fab-antigen complexes and the possible 
presence of free component-A in the medium. We 
observed the disappearance of the protein band 
corresponding to crotoxin, the appearance of pro- 
tein bands which can correspond to Fab-antigen 
complexes and did not find any free component-A 
(fig.2.). Therefore, Fabs do not promote the 
dissociation of crotoxin, and this cannot account 
for their protective effect. 
We also purified specific anti-component-A an- 
tibodies by ammonium sulfate precipitation and 
immunoaffinity chromatography on a component- 
A column. Although these antibodies reacted with 
crotoxin and cross-reacted with isolated 
component-B in ELISA, they were unable to 
neutralize its lethal potency and to inhibit its en- 
zymatic activity (table 2). 
4. CONCLUSION 
Rabbit antibodies raised against both crotoxin 
subunits were found to react or to cross-react with 
crotoxin and with crotoxin-like proteins from the 
venom of several Crotalus species. These an- 
tibodies do not cross-react with most other toxic 
and non-toxic phospholipases AZ from mammalian 
pancreas and snake venoms, in agreement with 
previous investigations [39,43]. We observed 
however that anti-component-B antibodies cross- 
react with some single-chain phospholipase A2 
neurotoxins from Crotalid and Viperid venoms, 
agkistrodontoxin and ammodytoxin A, but not 
with notexin, an Elapid single-chain phospholipase 
AZ toxin. The presence of crotoxin-like toxins in 
the venom of C. horridus atricaudatus, C. 
basiliscus and Crotalus tigris has been suggested on 
the basis of immunological cross-reactions with 
anti-crotoxin antibodies [44,45]. This appears to 
be in fact a weak argument because of significant 
cross-reactions of anti-component-B antibodies 
with the non-crotoxin-like toxins, agkistrodontox- 
in and ammodytoxin A. We also observed that 
anti-component-A antibodies cross-react with 
component-B whereas anti-component-B do not 
react with component-A, suggesting that the major 
antigenic determinants of component-B are not 
present on component-A. 
Antibodies directed to component-B were found 
to be able to neutralize the lethal potency of native 
crotoxin, in agreement with the early observations 
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of Da Silva and Bier [43]. On the other hand, an- 
tibodies directed to the non-catalytic subunit, 
component-A, were found to have no protective 
effect. The present investigation further shows that 
non-precipitating antibodies (Fab) are as potent as 
intact immunoglobulins, proving that neutraliza- 
tion of crotoxin results from the binding of Fabs to 
the toxin rather than from the formation of an im- 
munoprecipitate. The protective effect of anti- 
component-B Fabs was further investigated. We 
found that: (i) anti-component-B Fabs do not 
dissociate the crotoxin complex; (ii) concentrations 
of anti-component-B Fabs that neutralize the 
lethal potency of crotoxin inhibit its phospholipase 
activity. Taking into account the fact that alkyla- 
tion of crotoxin by p-bromophenacyl bromide 
simultaneously inactivates its phospholipase activi- 
ty and abolishes its lethal potency [46,47], this sug- 
gests that neutralization of crotoxin by 
non-precipitating Fabs might result from their bin- 
ding to epitope(s) belonging at least in part to the 
enzymatic site of the toxin. Further investigations 
carried out with monoclonal antibodies directed 
against component-B are in progress to examine 
this hypothesis. Preliminary results from this 
laboratory and from others [48] indicated that 
some monoclonal antibodies directed against 
component-B are indeed able to inhibit 
phospholipase activity of crotoxin and to 
neutralize its lethal potency. 
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